Endocrine Abstracts (2013) 32 P380 | DOI: 10.1530/endoabs.32.P380

High prevalence of the metabolic syndrome among newly diagnosed type 2 diabetes patients in Denmark

Jens Steen Nielsen1, Reimar W Thomsen2, Sinna Pilgaard Ulrichsen2, Anil Mor2, Jacob Volmer Stidsen1, Jørgen Rungby3, Søren Friborg1, Ivan Brandslund4, Jens Sandahl Christiansen5, Henrik Toft-Sørensen2 & Henning Beck-Nielsen1

1Department of Endocrinology, Diabetes Research Centre, Odense University Hospital, Odense, Denmark; 2Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; 3Department of Pharmacology, University of Aarhu, Aarhus, Denmark; 4Department of Biochemistry, Lillebaelt Hospital Vejle, Vejle, Denmark; 5Department of Internal Medicine and Endocrinology, Aarhus University Hospital, Aarhus, Denmark.

Few population-based data exist on the prevalence of the metabolic syndrome (MS) its components, and its association with subclinical inflammation and insulin resistance among patients newly diagnosed with type two diabetes (T2D).

We examined the MS according to IDF criteria by linkage primary data (waist circumference, fasting blood glucose, and high-sensitivity C-reactive protein (CRP)) with variables from the Danish diabetes database for adults (blood pressure and lipids) and a nationwide prescription database (antilipidemic, antihypertensive, and hypoglycemic drugs).

We included 525 newly diagnosed T2D patients (median age 60 years, 60% men), whereof 89.0% had MS. Age and gender were similar in MS and non-MS patients. Waist circumference was elevated in 98.1% of MS vs 34.5% of non-MS patients (prevalence ratio 2.84; 95% CI: 2.49–3.20). Most MS patients had elevated blood pressure (systolic ≥130, or diastolic ≥85, or antihypertensive drug): 94.4 vs 55.2% in non-MS patients (prevalence ratio 1.71; 95% CI: 1.48–1.94). Fasting blood glucose was increased in nearly all MS and non-MS patients. Triglycerides were elevated in 48.6% of MS and 3.4% of non-MS patients (prevalence ratio 14.10; 95% CI: 12.73–15.46). HDL-cholesterol was reduced in 33.6% of MS and 0.0% of non-MS patients. Increased C-peptide levels ≥300 pmol/l was more common in MS than non-MS patients (96.8 vs 77.6%, P=0.0005). 23.1% of the MS patients were previous hospital-diagnosed with cardiovascular disease vs 0% in non-MS. The median CRP was 2.40 mg/l (quartiles 1.00–5.10) in MS patients vs 1.20 mg/l (quartiles 0.60–3.50) in non-MS patients (P=0.006).

89% of the newly diagnosed T2D patients have the MS, with 90% having elevated waist circumference, blood pressure and blood glucose, and <50% having elevated triglycerides and reduced HDL-cholesterol. Elevated C-peptide levels are common in T2D patients with MS and their CRP level and risk of previous cardiovascular disease is higher than in non-MS patients.